20 results on '"Batus M"'
Search Results
2. OA10.02 Psychosocial Distress in Patients with Driver-Mutant Lung Cancer
3. P76.30 The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in Patients with EGFR Mutated Advanced NSCLC
4. P1.02 Chemotherapy with VMAT (Volumetric Modulated Arc Therapy) Radiation Therapy For Poor Risk Stage IIIA-C NSCLC Patients
5. P1.05 Clinical Factors Associated with Progression in Previously Treated Patients with Metastatic NSCLC on ANTI-PD-1 Therapy
6. OA03.01 Biomarkers of Autoimmune Toxicity in Metastatic SCLC Patients Receiving PD-1/PDL-1 Targeted Therapy
7. P1.21 RNA Pathway Enrichment in Serum Based Mass Spectroscopy Prognostic Analyses
8. OA01.02 Prognostic Value of Baseline Autoantibodies in Metastatic NSCLC Patients Receiving PD-/PDL-1 Targeted Immunotherapy
9. P2.04-69 Impact of Antibiotic Usage on Survival During Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer (NSCLC)
10. MA13.01 Associations Between Baseline Serum Biomarker Levels and Cachexia/Pre-Cachexia in Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients
11. P2.03-29 Circulating Levels of Ligands for Receptor Tyrosine Kinases May Contribute to an Immunosuppressive Tumor Microenvironment
12. P2.01-12 Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients
13. P3.01-19 Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients
14. P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated with Immunotherapy and Ramucirumab Plus Docetaxel.
15. P3.01-05 Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy
16. P2.01-61 Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy.
17. P2.12-16 Significant Tumor Regression and Toxicity with Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation
18. PS02.13 Rapid Progression in 100% PDL-1 expressing NSCLC
19. PUB057 Neutrophil to Lymphocyte Ratio Predicts Survival in Advanced NSCLC Patients Treated with Second-Line PD-1 Immune Checkpoint Inhibitors
20. Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.